Association of calpain 10 gene UCSNP-43 polymorphism (rs3792267) with polycystic ovarian syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20150452Keywords:
Polycystic ovarian syndrome, Gene polymorphism, Type 2 diabetes mellitus, Calpain-10Abstract
Background: The principle features of polycystic ovarian syndrome (PCOS) are insulin resistance (IR), hyperandrogenism (HA), obesity (Ob), oligo/anovulation and polycystic ovaries (PCO). PCOS is known to be associated with increased risk of type-2 diabetes mellitus (T2DM) and genes related to T2DM may also play a role in PCOS pathogenesis. Our aim is to study the association of CAPN-10 gene UCSNP-43 (rs3792267) polymorphism with PCOS.
Methods: Case-control study, involved 204 women with PCOS and 204 healthy, sex and age matched controls. Anthropometric and biochemical profile were taken in a well designed proforma. Isolation of deoxyribonucleic acid (DNA), and genotype analysis was done for all the study population using PCR-RFLP.
Results: No significant difference in allele and genotype frequencies of the CAPN-10, UCSNP- 43 (rs3792267) gene polymorphism were seen between the cases and controls. Frequency of A allele was 0.15 in PCOS and 0.19 in controls (OR 0.7207, CI 0.5 to 1.039 and p value 0.0793), indicates that the A allele is not associated with PCOS in our population, and show equal distribution of genotypes in PCOS patients and controls. The AA genotype conferred lack of association for developing PCOS (OR 0.4925, CI 0.1215 to 1.9968 and p value 0.3214). But the AA genotype showed elevated body mass index, waist to hip ratio, insulin resistance, triglyceride levels and decreased high density lipoprotein levels when compared to AG and GG genotypes of PCOS patients with controls.
Conclusions: In conclusion, there is no disease risk association of CAPN-10 gene UCSNP-43 (rs3792267) polymorphism with PCOS.
Metrics
References
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Position statement: Criteria for Defining PCOS as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. J Clin Endocrinol Metab 2006;91:4237-45.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the Polycystic ovarian syndrome: the complete task force report. Fertil and Steril 2009;91(2):456-88.
Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999; 22: 141-46.
Carmina E. Genetic and Environmental aspect of polycystic ovary syndrome. J Clin Endocrinol Invest 2003;26:1151-9.
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999; 84 :165-69.
Ehrmann DA. Glucose Intolerance in Polycystic Ovary Syndrome: Role of Beta cell In: Chang RJ, Heindel JJ, Dunaif A, eds. Polycystic Ovary Syndrome. New York: Marcel Dekker Inc. 2002: 89-103.
Horikawa Y, Oda N, Cox NJ, Li X, Orho-Melander M, Hara M, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000;26:163-75.
Evans JC, Frayling TM, Cassell PG, Saker PJ, Hitman GA, Walker M, et al. Studies of association between the gene for Calpain-10 and type 2 diabetes mellitus in the United Kingdom. Am J Hum Genet 2001;69:544-52.
Ehrmann DA, Schwarz PE, Hara M, Tang X, Horikawa Y, Imperial J, et al. Relationship of Calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:1669-73.
Gonzalez A, Abrill E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, et al. Comment: Calpain10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:3971-76.
Vollmert C, Hahn S, Lamina C, Huth C, Kolz M, Schopfer-Wendels A, et al. Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians. Am J Physiol Endocrinol Metab 2007; 292: E836-44.
Escobar-Morereale HF, Peral B, Villuendas G, Calvo RM, Sancho J, San Millan JL. Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism. Fertil Steril 2002; 77: 581-87.
Haddad L, Evans JC, Gharani N, Robertson C, Rush K, Wiltshire S, et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87:2606-10.
Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detecion, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3413-21.
Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991; 34: 416-22.
Reaven GM. Banting lecture. Role of insulin resistance in human disease. Diabetes 1998; 37:1595-07.
Chen SF, Lu XF, Yan WL, Huang JF, Gu DF. Variations in the Calpain 10 gene are associated with the risk of type 2 diabetes and hypertension in northern Han Chinese population. Chin Med J (Engl) 2007; 120: 2218-23.
Garant MJ, Kao WH, Brancati F, Coresh J, Rami TM, Hanish CL, et al. SNP 43 of CAPN10 and the risk of type 2 Diabetes in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 2002;51:231-37.
Shima Y, Nakanishi K, Odawara M, Kobayashi T, Ohta H. Association of SNP-19 genotype 22 in the Calpain-10 gene with elevated body mass index and hemoglobian A1c levels in Japanese. Clin Chim Acta 2003;336:89-96.
Carlsson E, Fredriksson J, Groop L, Ridderstale M. Variation in the Calpain-10 gene is associated with elevated triglycerides levels and reduced adipose tissue messenger ribonucleic acid expression in Swedish subjects. J Clin Endocrinol Metab 2004; 89:3601-05.
Govindan S, Ahamad SN, Vedicherla B, Kodati V, Rao KP, Ahuja YR, Hasan Q. Association of Progesterone receptor gene polymorphism (PROGINS) with endometriosis, uterine fibroids and breast cancer. Cancer Biomark 2007;3:73-8.
Kodati VL, Shetty P, Vattam K, Govindan S, Shaik NA and Hasan Q. Tumor necrosis factor alpha-C850T polymorphism is significantly associated with endometriosis in Asian Indian women. Fertil and Steril 2010;94(2):453-56.
Liang SJ, Hsu CS, Tzeng CR, Chen CH, and Hsu MI. Clinical and Biochemical parameters of Polycystic Ovary Syndrome between the age of 20 and 40. Hum reprod 2011;12:3443-49.
Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization studies. Am J Epidemiol 2009;169:505-14.
Chen X, Ni R, Mo Y, Li L, Yang D. Appropriate BMI levels for PCOS patients in Southern China. Hum Reprod 2010;25:1295-02.
Wiltgen D, Furtado L, Kohek MB, Spritzer PM. CAPN10 UCSNP-43, UCSNP-19 and UCSNP-63 polymorphisms and metabolic syndrome in polycystic ovary syndrome. Gynecol Endocrinol 2007;23(3):173-78.
Marquez JL, Pacheco A, Valdes P, Salazar LA. Association between CAPN10 UCSNP-43 gene polymorphism and polycystic ovary syndrome in Chilean women. Clin Chim Acta 2008;398(12):5-9.
Sreenan SK, Zhou YP, Otani K, Hansen PA, Currie KP, Pan CY, et al. Calpains play a role in insulin secretion and action. Diabetes 2001;50:2013-20.
Gonzalez A, Abril E, Roca A, Aragon MJ, Figueroa MJ, Velarde P, et al. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab 2003;88:5529-36.
Dasgupta S, Sirisha PVS, Neelaveni K, Anuradha K, Reddy BM. Association of CAPN10 SNPs and Haplotypes with Polycystic Ovary Syndrome among South Indian Women. PLoS ONE 2012;7(2):e32192.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovarian syndrome. Int J Obes Relat Metab Disord 2002;26:883-96.